Since their introduction just over ten years ago, biosimilar medicines have offered a less-costly option to provide biological medicines that have lost their exclusivity rights. Biosimilars have the potential to reduce the financial burden on healthcare systems, ultimately improving patient access to safe and effective biological medicines with proven efficacy and safety. Whilst their availability across Europe is growing rapidly and the US is more slowly on the rise (Quintiles, 2017), many clinicians remain unsure of what biosimilars are and how they should be used to optimise disease management.
This Learning Zone has been designed to provide an overview of biological medicines including their benefits and challenges, alongside a close-up look at emerging biosimilars and explain where they fit in current clinical practice. The centre provides clear information on what a biological medicine is, what a biosimilar is, the perceived differences between biosimilar and biological medicines, how they are developed and approved, and sources for further reading.
What are biological and biosimilar medicines? Discover more about their development, as well as the manufacturing and regulatory processes here.
Biosimilars are molecular versions of existing reference biologics that have lost exclusivity. Find out how biosimilars are evaluated to ensure they match the reference medicine here.
Get a clear understanding of the various scientific terms used throughout the knowledge centre and further your knowledge of biosimilars through external societies and organisations.
Explore our list of upcoming events that are relevant to biological medicines and biosimilars, containing information on key conferences, congresses and meetings.